R788
Phase 3Small molecule
R788 is one of 56 small molecule programs targeting Arthritis. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
159 competitors in Arthritis
#DrugCompanyPhaseTrials
1Aleve
Alnylam PharmaceuticalsPhase 3
Stelara
Johnson & JohnsonPhase 3
Bimzelx
UCBPhase 3
Ilaris
NovartisPhase 3
Kenalog
BBassett Healthcare
Phase 3
Remicade
OOrganon and Co
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
SHR-1314
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Botulinum Toxin
MMeshalkin Research Institute of Pathology of Circulation
Phase 3
CZP Q4W
UCBPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for R788. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRigel Pharmaceuticals